Cargando…

Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy

BACKGROUND: Cardiomyopathy is a leading cause of late morbidity and mortality in childhood cancer survivors (CCS). Evidence-based guidelines recommend risk-stratified screening for cardiomyopathy, but the management approach for abnormalities detected when screening asymptomatic young adult CCS is p...

Descripción completa

Detalles Bibliográficos
Autores principales: Aziz-Bose, Rahela, Margossian, Renee, Ames, Bethany L., Moss, Kerry, Ehrhardt, Matthew J., Armenian, Saro H., Yock, Torunn I., Nekhlyudov, Larissa, Williams, David, Hudson, Melissa, Nohria, Anju, Kenney, Lisa B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537072/
https://www.ncbi.nlm.nih.gov/pubmed/36213355
http://dx.doi.org/10.1016/j.jaccao.2022.05.010
_version_ 1784803117355761664
author Aziz-Bose, Rahela
Margossian, Renee
Ames, Bethany L.
Moss, Kerry
Ehrhardt, Matthew J.
Armenian, Saro H.
Yock, Torunn I.
Nekhlyudov, Larissa
Williams, David
Hudson, Melissa
Nohria, Anju
Kenney, Lisa B.
author_facet Aziz-Bose, Rahela
Margossian, Renee
Ames, Bethany L.
Moss, Kerry
Ehrhardt, Matthew J.
Armenian, Saro H.
Yock, Torunn I.
Nekhlyudov, Larissa
Williams, David
Hudson, Melissa
Nohria, Anju
Kenney, Lisa B.
author_sort Aziz-Bose, Rahela
collection PubMed
description BACKGROUND: Cardiomyopathy is a leading cause of late morbidity and mortality in childhood cancer survivors (CCS). Evidence-based guidelines recommend risk-stratified screening for cardiomyopathy, but the management approach for abnormalities detected when screening asymptomatic young adult CCS is poorly defined. OBJECTIVES: The aims of this study were to build upon existing guidelines by describing the expert consensus–based cardiomyopathy screening practices, management approach, and clinical rationale for the management of young adult CCS with screening-detected abnormalities and to identify areas of controversy in practice. METHODS: A multispecialty Delphi panel of 40 physicians with expertise in cancer survivorship completed 3 iterative rounds of semi-open-ended questionnaires regarding their approaches to the management of asymptomatic young adult CCS at risk for cardiomyopathy (screening practices, referrals, cardiac testing, laboratory studies, medications). Consensus was defined as ≥90% panelist agreement with recommendation. RESULTS: The response rate was 100% for all 3 rounds. Panelists reached consensus on the timing and frequency of echocardiographic screening for anthracycline-associated cardiomyopathy, monitoring during pregnancy, laboratory testing for modifiable cardiac risk factors, and referral to cardiology for ejection fraction ≤50% or preserved ejection fraction with diastolic dysfunction. Controversial areas (<75% agreement) included chest radiation dose threshold to merit screening, indications for advanced cardiac imaging and cardiac serum biomarkers for follow-up of abnormal echocardiographic findings, and medical management of asymptomatic left ventricular systolic dysfunction. CONCLUSIONS: Expert practice is largely consistent with existing risk-based screening guidelines. Some recommendations for managing abnormalities detected on screening echocardiography remain controversial. The rationale offered by experts for divergent approaches may help guide clinical decisions in the absence of guidelines specific to young adult CCS.
format Online
Article
Text
id pubmed-9537072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95370722022-10-08 Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy Aziz-Bose, Rahela Margossian, Renee Ames, Bethany L. Moss, Kerry Ehrhardt, Matthew J. Armenian, Saro H. Yock, Torunn I. Nekhlyudov, Larissa Williams, David Hudson, Melissa Nohria, Anju Kenney, Lisa B. JACC CardioOncol Original Research BACKGROUND: Cardiomyopathy is a leading cause of late morbidity and mortality in childhood cancer survivors (CCS). Evidence-based guidelines recommend risk-stratified screening for cardiomyopathy, but the management approach for abnormalities detected when screening asymptomatic young adult CCS is poorly defined. OBJECTIVES: The aims of this study were to build upon existing guidelines by describing the expert consensus–based cardiomyopathy screening practices, management approach, and clinical rationale for the management of young adult CCS with screening-detected abnormalities and to identify areas of controversy in practice. METHODS: A multispecialty Delphi panel of 40 physicians with expertise in cancer survivorship completed 3 iterative rounds of semi-open-ended questionnaires regarding their approaches to the management of asymptomatic young adult CCS at risk for cardiomyopathy (screening practices, referrals, cardiac testing, laboratory studies, medications). Consensus was defined as ≥90% panelist agreement with recommendation. RESULTS: The response rate was 100% for all 3 rounds. Panelists reached consensus on the timing and frequency of echocardiographic screening for anthracycline-associated cardiomyopathy, monitoring during pregnancy, laboratory testing for modifiable cardiac risk factors, and referral to cardiology for ejection fraction ≤50% or preserved ejection fraction with diastolic dysfunction. Controversial areas (<75% agreement) included chest radiation dose threshold to merit screening, indications for advanced cardiac imaging and cardiac serum biomarkers for follow-up of abnormal echocardiographic findings, and medical management of asymptomatic left ventricular systolic dysfunction. CONCLUSIONS: Expert practice is largely consistent with existing risk-based screening guidelines. Some recommendations for managing abnormalities detected on screening echocardiography remain controversial. The rationale offered by experts for divergent approaches may help guide clinical decisions in the absence of guidelines specific to young adult CCS. Elsevier 2022-08-16 /pmc/articles/PMC9537072/ /pubmed/36213355 http://dx.doi.org/10.1016/j.jaccao.2022.05.010 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Aziz-Bose, Rahela
Margossian, Renee
Ames, Bethany L.
Moss, Kerry
Ehrhardt, Matthew J.
Armenian, Saro H.
Yock, Torunn I.
Nekhlyudov, Larissa
Williams, David
Hudson, Melissa
Nohria, Anju
Kenney, Lisa B.
Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy
title Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy
title_full Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy
title_fullStr Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy
title_full_unstemmed Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy
title_short Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy
title_sort delphi panel consensus recommendations for screening and managing childhood cancer survivors at risk for cardiomyopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537072/
https://www.ncbi.nlm.nih.gov/pubmed/36213355
http://dx.doi.org/10.1016/j.jaccao.2022.05.010
work_keys_str_mv AT azizboserahela delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT margossianrenee delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT amesbethanyl delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT mosskerry delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT ehrhardtmatthewj delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT armeniansaroh delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT yocktorunni delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT nekhlyudovlarissa delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT williamsdavid delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT hudsonmelissa delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT nohriaanju delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy
AT kenneylisab delphipanelconsensusrecommendationsforscreeningandmanagingchildhoodcancersurvivorsatriskforcardiomyopathy